Case Reports in Medicine

Case Reports in Medicine / 2011 / Article

Case Report | Open Access

Volume 2011 |Article ID 262674 |

Riccardo Cazzuffi, Nunzio Calia, Franco Ravenna, Claudio Pasquini, Sara Saturni, Giorgio Narciso Cavallesco, Francesco Quarantotto, Rosa Rinaldi, Annaluisa Cogo, Gaetano Caramori, Alberto Papi, "Primary Pulmonary Epithelioid Hemangioendothelioma: A Rare Cause of PET-Negative Pulmonary Nodules", Case Reports in Medicine, vol. 2011, Article ID 262674, 6 pages, 2011.

Primary Pulmonary Epithelioid Hemangioendothelioma: A Rare Cause of PET-Negative Pulmonary Nodules

Academic Editor: A. Curt
Received11 Feb 2011
Accepted16 May 2011
Published21 Aug 2011


We report here a case of primary pulmonary epithelioid hemangioendothelioma diagnosed in a 67-year-old Caucasian man, presenting with exertion dyspnoea, dry cough, and multiple bilateral pulmonary nodules revealed by computed tomography. At the 18F-fluorodeoxyglucose positron emission tomography, these nodules were negative. The histopathological diagnosis was made on a pulmonary wedge resection (performed during video-thoracoscopic surgery).

1. Introduction

Pulmonary epithelioid hemangioendothelioma (PEH) is a rare, low- to intermediate-grade tumor of endothelial origin [1] with around 120 cases reported in the literature [2]. At the onset, the patients are usually asymptomatic or present with nonspecific symptoms (such as weight loss, fatigue, dyspnoea, cough, and chest pain). Chest imaging usually shows the presence of multiple, bilateral small pulmonary lesions. The diagnosis usually requires a lung biopsy. The treatment is still not standardized. Surgery is suggested in presence of a solitary nodule or few unilateral nodules. Instead if the lesions are unresectable or multiple and bilateral several chemotherapy protocols have been used. The prognosis is variable with a median survival of 4-5 years.

2. Case Report

A 67-year-old Caucasian man, lifelong nonsmoker, with no prior history of lung diseases, was referred to our university hospital for the presence, in the last 3 months, of exertion dyspnoea (grade 1 according to the Medical Research Council scale [3]) and dry cough. He had worked as an employee without occupational exposures of clinical relevance. His past medical history was characterized by an herniated lumbar disc, systemic arterial hypertension (treated with calcium blockers), diabetes mellitus (treated with oral hypoglycaemic agents), and polycythemia vera (diagnosed in 2007 and treated from 2008 with hydroxyurea). Physical examination was unremarkable. Arterial blood gases analysis performed with the patient breathing room air demonstrated normal values (pH 7.40, PaCO2 43 mmHg, PaO2 91 mmHg, and bicarbonate level 26 mmoL/L). Routine laboratory tests were within the normal range except for those listed in Table 1. Serum levels of neoplastic markers were within normal range, including carcinoembryonic antigen (2.7 ng/mL), prostate-specific antigen (3.75 ng/mL), and CA19.9 (15 U/mL). Also the serum levels of angiotensin-converting enzyme (11 IU/mL) and β2 microglobulin (2.50 mg/mL) were within normal limits.

White blood cells12.01 × 103 Normal range 4.00–11 × 103/μL
Red blood cells4.80 × 106Normal range 4.50–6.50 × 106/μL
HGB15.9Normal range 13.0–18 g/dl
HCT49Normal range 40–54%
MCV103Normal range 76–96 fl
MCH33.1Normal range 27.0–32.0 pg/dl
MCHC32.3Normal range 30.0–35.0 g/dl
PLT434Normal range 150–450 × 103/μL
Blood neutrophils9.56 × 103Normal range 2.00–7.50 × 103/μL
Blood lymphocytes1.92 × 103Normal range 1.50–5.00 × 103/μL
Blood monocytes0.43 × 103Normal range 0.20–1.00 × 103/μL
Blood eosinophils0.08 × 103Normal range 0.04–0.40 × 103/μL
Blood basophils0.01 × 103/
PT1.09Normal range 0.85–1.20 INR
APTT1.22Normal range 0.85–1.20 ratio
Glycaemia99Normal range 70–11 mg/dl
Creatinine1.2Normal range 0.9–1.4 mg/dl

APTT: Activated thromboplastin time. HCT: Hematocrit. HGB: Haemoglobin. LDH: Lactate dehydrogenase. MCH: Mean corpuscular Haemoglobin. MCV: Mean blood cell volume. MCHC: Mean cell haemoglobin concentration. PLT: Platelets. PT: Prothrombin time.

The pulmonary function tests showed the presence of a restrictive pattern with a vital capacity (VC) of 3.14 litres (70% of the predicted value), a forced vital capacity (FVC) of 3.11 litres (72% of the predicted value), forced expiratory volume in one second (FEV1) of 2.55 litres (76.5% of predicted value), a FEV1/VC ratio of 81% (108% of the predicted value) and a total lung capacity (TLC), 5.35 litres (73.3% of the predicted value). DLCO was in the normal range (Figure 1).

The chest radiography and a computed tomography of the chest (performed with iodine intravenous contrast medium) showed the presence of multiple bilateral pulmonary nodules (with a diameter variable between 3 mm and 3 cm) without contrast enhancement and the presence of one nodule (with the diameter of 2 cm) in the fourth hepatic segment showing late-phase contrast enhancement and another in the spleen (with the diameter of 1 cm) with cystic features (Figure 2).

Interestingly, at the 18F-fluorodeoxyglucose positron emission tomography (PET), all these nodules were not showing any uptake of the tracer (Figure 3).

The fiberoptic bronchoscopy was normal. A transbronchial lung biopsy and an ultrasound-guided transthoracic lung biopsy were both nondiagnostic.

The final diagnosis of pulmonary epithelioid hemangioendothelioma was made by pulmonary wedge resection of a nodule located in the left lower lobe by video-thoracoscopic surgery. Histopathological examination of the resected tissue revealed round- to oval-shaped nodules, with a central sclerotic, hypocellular zone, and peripheral zone rich of cells. There was tumour diffusion into the adjacent bronchioles and the alveolar spaces with micropolypoid aspects. The extracellular stroma consisted of an abundant matrix of chondroid, hyaline, mucinous, or myxomatous appearance.

The neoplastic cells were of polygonal shape and eosinophilic with round nuclei and uniform small to moderately sized nucleoli. Some cells had cytoplasmic vacuoles.

Immunohistochemical studies demonstrated that the neoplastic cells are endothelial cells immunoreactive for Von Willebrand factor, CD31, CD34, and vimentin (Figure 4).

Immunostaining for other markers (including caudal type homeobox transcription factor 2 (CDX2), cytokeratin (CK) 20, CK7, prostate-specific antigen (PSA), pan-cytokeratin, chromogranin, epithelial membrane antigen (EMA), HMB45, progesterone receptor, and thyroid transcription factor (TTF)-1) was negative.

3. Discussion

Pulmonary epithelioid hemangioendothelioma (PEH) is a rare, low- to intermediate-grade tumor of endothelial origin [1]. Epithelioid hemangioendothelioma can arise from many organs, including lungs, liver, bone, and soft tissue, simultaneously or sequentially. When this occurs, it may be difficult to determinate if the tumor is multicentric from the beginning or there is a primary lesion with metastases to the other tissues [4]. Around 120 cases have been reported in literature [2, Table 2], only five of them were in Italian patients [5, 1518]. Mean (SD) age of patients is 40.1 (17.5) years, and 73% are females [6]. Interestingly, our patient is instead a 67-year-old male. Most patients are asymptomatic at presentation, and some are complaining of weight loss, fatigue, dyspnoea, fever, pleuritic chest pain, mild nonproductive cough, and haemoptysis [19]. In most cases, the physical examination is normal, but few cases of digital clubbing and pleural effusions have been reported [1, 6].

Review of the literatureOur case report

Female/male ratio 3 : 1 femaleMale

Mean (SD) age40.1 (17.5) years67 years

SymptomsWeight loss, fatigue, and respiratory symptoms (dyspnoea, chest pain, mild nonproductive cough, and mild haemoptysis)Dyspnoea and dry cough

Chest radiography and computed tomographyUsually multiple bilateral pulmonary nodulesMultiple bilateral pulmonary nodules


Metastatic sitesLymph nodes, liver, bone, skin, serosal membranes, spleen, tonsils, retroperitoneum, kidney and central nervous systemSingle spleen and liver metastatic nodules

Immunohistochemical featuresFactor VIII von Willebrand factor+, CD31+, or CD34+Factor VIII von Willebrand factor+, CD31+, CD34+

5-year survival (%)60%Alive for eight months then lost at the follow up

Obtained with the data from [418].

The most characteristic feature of PEH on chest radiographs or CT is the presence of multiple perivascular nodules with well- or ill-defined margins in both lungs. The nodules may range in size up to 2 cm, but most of them are ≤1 cm in diameter; they are usually found near medium-sized vessels and bronchi [1]. This radiological presentation is suggestive of many lung diseases (Table 3).

Primary lung cancer (particularly bronchioloalveolar carcinoma)
Lymphoid tumors and myeloma
Leukaemic infiltrates
Benign vascular tumors (hemangioma and lymphangioma)
Malignant vascular tumors (angiosarcoma and Kaposi’s sarcoma)
Neuroendocrine tumourlets
Nodular lesions in pulmonary fibrosis
Infections (tuberculosis, nocardiosis, aspergillosis, and histoplasmosis)
Langerhan’s cell histiocytosis
Pulmonary arteriovenous malformations

Obtained with the data from [4, 5, 9, 1214].

Some authors consider 18F-fluorodeoxyglucose positron emission tomography an important tool for PEH diagnosis [7]; however, in our patient, the PET was negative, suggesting that a negative PET cannot exclude PEH. Unfortunately, we do not have a molecular explanation for this finding but may be related to a low proliferation rate of the neoplastic cells.

The diagnosis of PEH is made on the basis of the histopathological features and confirmed using immunohistochemical staining for endothelial cell markers, such as against factor VIII-related von Willebrand antigen, CD31 or CD34 [2, 4, 13, 20, 21].

The prognosis is variable. The 5-year survival is around 60% (range 47–71%). In fact, there are two groups of PEH at the clinical presentation: (1) one asymptomatic, with a solitary pulmonary nodule or unilateral multiple nodules. Usually they can be managed with surgery alone, and lymphatic invasion is unlikely. Their prognosis is good with a median survival of more than 10 years; (2) another symptomatic group presents with multiple bilateral pulmonary nodules or pleural effusion with scarce response to chemotherapy. The prognosis of this group is poor [11]. Most patients die from pulmonary insufficiency as a result of an increasing number of tumor nodules [9]. Hematogeneous metastases are rare and have been described especially in the liver but also in other sites [2, 4].

The treatment of PEH is not standardized. Surgery alone is indicated in the presence of a single pulmonary nodule or unilateral multiple nodules. Lung transplantation should be considered in patients with vascular infiltration [10].

Various chemotherapies have been reported for unresectable or metastatic PEH, with variable effectiveness [22]. Other authors have suggested a role for the hormonal therapy (antiestrogens and progesterone) in patients with diffuse disease if the neoplastic cells express estrogen and progesterone receptors [23]. A slight regression of the pulmonary lesions was also obtained with interferon (IFN)-2α, probably for its antiangiogenic activity [24]. Thalidomide and IFN-α have also been proposed for unresectable cases [22]. Some beneficial results were also obtained with bevacizumab, a monoclonal antibody that blocks human VEGF-A [22, 25]. The neoplastic cells express glucocorticoid receptors and the enzyme 11β-hydroxysteroid dehydrogenase involved in the synthesis of the steroids, suggesting a potential role for steroid modulators [26].

In conclusion, we had the opportunity to observe an unusual primary pulmonary hemangioepithelioma in an old male patient, and interestingly, in comparison with the published literature, the neoplastic lesions were PET negative. Again, as previously suggested [27], we stress the importance of starting an international clinical registry of this unusual neoplasm.


Riccardo Cazzuffi and Gaetano Caramori have equally contributed to this work.


  1. H. Baba, M. Tomiyasu, H. Makino, A. Yamamoto, H. Yokoyama, and Y. Oshiro, “Surgical resection of a primary pulmonary epithelioid hemangioendothelioma in bilateral lungs,” General Thoracic and Cardiovascular Surgery, vol. 58, no. 8, pp. 431–433, 2010. View at: Publisher Site | Google Scholar
  2. O. Leleu, F. Lenglet, C. Clarot, P. Kleinmann, and V. Jounieaux, “Pulmonary epithelioid haemangioendothelioma: reports of three cases and a review of the literature,” Revue des Maladies Respiratoires, vol. 27, no. 7, pp. 778–783, 2010. View at: Publisher Site | Google Scholar
  3. J. C. Bestall, E. A. Paul, R. Garrod, R. Garnham, P. W. Jones, and J. A. Wedzicha, “Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease,” Thorax, vol. 54, no. 7, pp. 581–586, 1999. View at: Google Scholar
  4. B. Ye, W. Li, X. Y. Liu et al., “Multiple organ metastases of pulmonary epithelioid haemangioendothelioma and a review of the literature,” Medical Oncology, vol. 27, no. 1, pp. 49–54, 2010. View at: Publisher Site | Google Scholar
  5. G. A. Rossi, P. Tomà, O. Sacco et al., “A 14-yr-old male with dyspnoea, productive cough and chest pain,” European Respiratory Journal, vol. 22, no. 2, pp. 387–391, 2003. View at: Publisher Site | Google Scholar
  6. R. M. S. Amin, K. Hiroshima, T. Kokubo et al., “Risk factors and independent predictors of survival in patients with pulmonary epithelioid haemangioendothelioma. Review of the literature and a case report,” Respirology, vol. 11, no. 6, pp. 818–825, 2006. View at: Publisher Site | Google Scholar
  7. S. Watanabe, F. Yano, T. Kita et al., “18F-FDG-PET/CT as an indicator for resection of pulmonary epithelioid hemangioendothelioma,” Annals of Nuclear Medicine, vol. 22, no. 6, pp. 521–524, 2008. View at: Publisher Site | Google Scholar
  8. N. Tochigi, K. Tsuta, A. M. Maeshima et al., “Malignant pulmonary epithelioid hemangioendothelioma with hilar lymph node metastasis,” Annals of Diagnostic Pathology, vol. 15, no. 3, pp. 207–212, 2011. View at: Publisher Site | Google Scholar
  9. T. Schattenberg, R. Kam, M. Klopp et al., “Pulmonary epithelioid hemangioendothelioma: report of three cases,” Surgery Today, vol. 38, no. 9, pp. 844–849, 2008. View at: Publisher Site | Google Scholar
  10. P. Bagan, M. Hassan, F. L. P. Barthes et al., “Prognostic factors and surgical indications of pulmonary epithelioid hemangioendothelioma: a review of the literature,” Annals of Thoracic Surgery, vol. 82, no. 6, pp. 2010–2013, 2006. View at: Publisher Site | Google Scholar
  11. Y. Ouadnouni, M. Bouchikh, A. Achir et al., “Pulmonary epithelioid hemangioendothelioma: a case report,” Cases Journal, vol. 2, no. 9, article no. 8235, 2009. View at: Publisher Site | Google Scholar
  12. L. Azcárate Perea, E. Oliveros Acebes, N. Moreno Mata, R. Salomón Pérez, E. Vilalta Castel, and F. González Aragoneses, “Pulmonary epithelioid hemangioendothelioma,” Archivos de Bronconeumologia, vol. 45, no. 9, pp. 466–468, 2009. View at: Publisher Site | Google Scholar
  13. A. Weissferdt and C. A. Moran, “Primary vascular tumors of the lungs: a review,” Annals of Diagnostic Pathology, vol. 14, no. 4, pp. 296–308, 2010. View at: Publisher Site | Google Scholar
  14. N. J. Mayer, W. A. H. Wallace, and H. H. Kamel, “Nodular lesions of the lung: a practical approach to histological diagnosis,” Current Diagnostic Pathology, vol. 9, no. 3, pp. 188–198, 2003. View at: Publisher Site | Google Scholar
  15. V. Poletti, “Epithelioid haemangioendothelioma of the lung imitating clinical features of pulmonary histiocytosis X,” Monaldi Archives for Chest Disease, vol. 52, no. 4, pp. 346–348, 1997. View at: Google Scholar
  16. G. Paciocco, U. Caterino, and D. D'Auria, “Epithelioid haemangioendothelioma of the lung: a high malignancy case,” Monaldi Archives for Chest Disease, vol. 54, no. 3, pp. 231–233, 1999. View at: Google Scholar
  17. A. Sortini, M. Santini, P. Carcoforo, D. Sortini, E. Pozza, and I. Donini, “Primary lung epithelioid hemangio-endothelioma with multiple bilateral metachronous localizations: case report and review,” International Surgery, vol. 85, no. 4, pp. 336–338, 2000. View at: Google Scholar
  18. F. Massera, R. Delfanti, G. Rocco, P. Antonelli, M. Donghi, and M. Robustellini, “Pulmonary epithelioid haemangioendothelioma mimicking bronchogenic carcinoma,” Journal of Cardiovascular Surgery, vol. 45, no. 4, pp. 397–398, 2004. View at: Google Scholar
  19. J. J. Erasmus, H. P. McAdams, and M. S. Carraway, “A 63-year-old woman with weight loss and multiple lung nodules,” Chest, vol. 111, no. 1, pp. 236–238, 1997. View at: Google Scholar
  20. M. Miettinen, A. E. Lindenmayer, and A. Chaubal, “Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens—evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor,” Modern Pathology, vol. 7, no. 1, pp. 82–90, 1994. View at: Google Scholar
  21. W. D. Travis, E. Brambilla, H. K. Mueller-Hermelink, and C. C. Harris, Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, WHO Classification of Tumours, IARC Press, Lyon, France, 2004.
  22. L. Belmont, L. Zemoura, and L. J. Couderc, “Pulmonary epithelioid haemangioendothelioma and bevacizumab,” Journal of Thoracic Oncology, vol. 3, no. 5, pp. 557–558, 2008. View at: Publisher Site | Google Scholar
  23. N. P. Ohori, S. A. Yousem, E. Sonmez-Alpan, and T. V. Colby, “Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung,” American Journal of Clinical Pathology, vol. 96, no. 4, pp. 529–535, 1991. View at: Google Scholar
  24. E. Radzikowska, E. Szczepulska-Wójcik, M. Chabowski, K. Oniszh, R. Langfort, and K. Roszkowski, “Pulmonary epithelioid haemangioendothelioma—interferon 2-alpha treatment—case report,” Pneumonologia i Alergologia Polska, vol. 76, no. 4, pp. 281–285, 2008. View at: Google Scholar
  25. Y. H. Kim, M. Mishima, and A. Miyagawa-Hayashino, “Treatment of pulmonary epithelioid hemangioendothelioma with bevacizumab,” Journal of Thoracic Oncology, vol. 5, no. 7, pp. 1107–1108, 2010. View at: Publisher Site | Google Scholar
  26. Y. Kumazawa, K. Maeda, M. Ito et al., “Expression of glucocorticoid receptor and 11β hydroxysteroid dehydrogenase in a case of pulmonary epithelioid haemangioendothelioma,” Molecular Pathology, vol. 55, no. 1, pp. 61–64, 2002. View at: Publisher Site | Google Scholar
  27. J. Kpodonu, C. Tshibaka, and M. G. Massad, “The importance of clinical registries for pulmonary epithelioid hemangioendothelioma,” Chest, vol. 127, no. 5, pp. 1870–1871, 2005. View at: Publisher Site | Google Scholar

Copyright © 2011 Riccardo Cazzuffi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.